NEI Research News

A new study reveals how the eye resolves inflammation in the eye disease autoimmune uveitis.

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A’s pro-inflammatory activity, according to a new NEI study.

Robert Nussenblatt, M.D., chief of the Laboratory of Immunology at the National Eye Institute (NEI), died on April 17 at age 67.

NIH scientists have simplified manufacturing and dosing of a potential drug candidate for the autoimmune eye disease uveitis—a vision-threatening condition that accounts for about 15 percent of blindness in the U.S.

Bugs in your eyes may be a good thing. Resident microbes living on the eye are essential for immune responses that protect the eye from infection, new research shows.

The inflammatory eye disorder autoimmune uveitis occurs when a person’s immune system goes awry, attacking proteins in the eye.

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

A preliminary clinical trial, conducted by researchers at the National Institutes of Health (NIH), found that an investigational treatment for uveitis seems to have many fewer side effects than existing therapies

In a small preliminary study, researchers at the National Institutes of Health (NIH) have discovered a possible new treatment for uveitis, a potentially blinding eye disease.